Re: insulin price
Sure, Afrezza costs have gone up more than Afrezza revenues. Those increased costs have gone up because Mannkind is finally generating enough funds to actually market Afrezza with some semblance of normality, probably with the thought that PBMs, insurance cos., and endos can be overcome by avid Afrezza users. Even now, Afrezza manufacturing unit costs are way too high because of the underutilized manufacturing facility in Danbury, CT. The facility can be expanded to produce something like $2 billion/yr. in Afrezza sales, and gross Afrezza sales this year probably won't exceed $40 million (corrected). JMHO.